Published in:
01-06-2017 | Erratum
Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
Published in: Breast Cancer Research and Treatment | Issue 3/2017
Login to get accessExcerpt
In the original publication of the article, the panel for estrogen receptor (ER) in Fig. 2c was incorrectly published. The corrected Fig. 2 is given in this erratum.
Fig. 2
IGF-1 signaling pathway activation in HBD-ESR1 mutants. a Ingenuity pathway analysis (IPA) to identify activation of signaling pathways in mutant MCF-7 versus ZR-75B. b Total cellular extracts were analyzed for phosphorylation and expression of ER, IGF1Rβ, IRS-1, and mTOR; GAPDH was used as a loading control. Immunoblots show a representative example of three experiments. c Total cellular extracts were analyzed for phosphorylation and expression of ERα, IGF1Rβ, IRS-1, and mTOR; GAPDH was used as a loading control. Immunoblots show a representative example of three different experiments
× ![]()
…